IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options to purchase an aggregate of 221,000 shares of common stock to six newly hired employees on May 28, 2026. The awards were made under the 2023 Employment Inducement Incentive Award Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $29.34, matching the Nasdaq Global Select Market closing price on the grant date, a 10-year term, and vest over four years, subject to continued service.

Positive

• Equity incentives align six new employees with long-term shareholder interests
• Exercise price set at market closing price of $29.34 per share
• 10-year option term supports long-term employee retention and planning

Negative

• 221,000 new stock options introduce potential future share dilution for existing holders
• Vesting contingent on continued service may limit immediate retention certainty

News Market Reaction – IDYA

+0.44%

1 alert

+0.44% Session close to close

$2.58B Market Cap

2.87K Volume

In the May 29 session, IDYA gained 0.44%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine non-qualified stock option grants covering 221,000 shares to six n...

Analysis

This announcement details routine non-qualified stock option grants covering 221,000 shares to six new employees under Nasdaq Listing Rule 5635(c)(4). It follows a series of significant clinical and regulatory milestones, including strong Phase 2/3 data, RTOR plans, and substantial liquidity of $972.9M. Investors may monitor how continued hiring, ongoing trial readouts, and potential use of the effective S-3ASR shelf interact with the stock’s position below its 200-day moving average.

Key Figures

Inducement options granted: 221,000 shares New hires: 6 employees Option exercise price: $29.34 per share +3 more

6 metrics

Inducement options granted 221,000 shares Non-qualified stock options to six newly hired employees under 2023 Inducement Plan

New hires 6 employees Recipients of inducement stock option grants

Option exercise price $29.34 per share Equal to Nasdaq closing price of IDEAYA common stock on May 28, 2026

Option term 10 years Duration of non-qualified stock options granted

Vesting period 4 years Options vest over four years subject to continued service

Initial vesting tranche 25% Vests on first anniversary of vesting commencement date

Historical Context

5 past events · Latest: May 26 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 26	Conference participation	Neutral	+0.9%	Announced participation in the 2026 Jefferies Global Healthcare Conference.
May 05	Earnings and update	Positive	-0.3%	Reported Q1 2026 results with pivotal OptimUM-02 win and strong liquidity.
May 01	Inducement grants	Neutral	-3.1%	Granted 237,800 stock options to new hires under the 2023 Inducement Plan.
Apr 30	RTOR submission plan	Positive	+3.7%	Planned FDA RTOR NDA submission after positive OptimUM-02 topline results.
Apr 21	ASCO data preview	Positive	-5.3%	Announced late-breaking ASCO 2026 oral presentation of full OptimUM-02 data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed reactions: strong clinical wins and ASCO-related updates sometimes prompted gains but also notable selloffs, while routine items like conferences and prior inducement grants saw modest or negative moves.

Recent Company History

Over the past two months, IDEAYA reported multiple key milestones. On Apr 9 and Apr 13, it highlighted a Phase 1 ADC collaboration with AstraZeneca and strong Phase 2/3 darovasertib data. An Apr 30 RTOR announcement and an upcoming ASCO 2026 oral presentation on OptimUM-02 further underscored clinical momentum. The May 5 Q1 2026 update emphasized a pivotal win and liquidity of $972.9M. Against this backdrop, today’s Nasdaq Rule 5635(c)(4) inducement grants continue a pattern of periodic hiring-related equity awards.

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4)

2 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 221,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., May 29, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 28, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 221,000 shares of the Company's common stock to six newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $29.34 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302785227.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What inducement grants did IDEAYA Biosciences (NASDAQ: IDYA) announce on May 29, 2026?

IDEAYA Biosciences announced non-qualified stock options for 221,000 shares granted to six new employees. According to IDEAYA, these options were issued under the 2023 Employment Inducement Incentive Award Plan as material inducements for joining the company under Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of the new IDEAYA (IDYA) inducement stock options?

The inducement stock options have an exercise price of $29.34 per share. According to IDEAYA, this price equals the closing price of IDEAYA common stock on the Nasdaq Global Select Market on May 28, 2026, the date the options were granted.

How do the IDEAYA (IDYA) inducement options vest for the six new employees?

The IDEAYA inducement options vest over four years, subject to continued service. According to IDEAYA, 25% vests on the first anniversary of the vesting commencement date, and the remaining 75% vests in equal monthly installments over the following three years.

What is the term length of the IDEAYA (IDYA) inducement stock options granted in May 2026?

The inducement stock options have a 10-year term from the grant date. According to IDEAYA, this long duration allows new employees extended time to potentially benefit from future share price appreciation, assuming they satisfy the vesting and continued service conditions.

Under which plan were the May 2026 IDEAYA (IDYA) inducement options granted?

The options were granted under the 2023 Employment Inducement Incentive Award Plan. According to IDEAYA, this plan is used exclusively for equity awards to new hires or rehires as employment inducements, in line with Nasdaq Listing Rule 5635(c)(4) requirements.

How might the 221,000 IDEAYA (IDYA) inducement options affect existing shareholders?

The 221,000 inducement options could create future dilution if exercised, modestly increasing IDEAYA’s share count. According to IDEAYA, these options are intended to attract and retain key talent by linking compensation to long-term stock performance and company growth.